多西他赛和吉西他滨治疗非小细胞肺癌的时辰药效学  

The chronopharmacodynamics of docetaxel and gemcitabine in treating non-small cell lung cancer

作　　者：赵文艳[1] 钟皎[1] 吴福林[1] 

机构地区：[1]无锡市第二人民医院药剂科,214002

出　　处：《江苏医药》2011年第24期2907-2909,共3页Jiangsu Medical Journal

基　　金：江苏省卫生厅临床医学科研课题(P200611)

摘　　要：目的比较多西他赛和吉西他滨不同时间点给药的疗效及不良反应。方法病理诊断的210例Ⅲ、Ⅳ期非小细胞肺癌(NSCLC)患者随机均分为六组,分别于第1、8天的8:00(D1组)、14:00(D2组)和20:00(D3组)给予多西他赛40mg/m2静脉滴注;G1、G2、G3组分别于上述时间点给予吉西他滨1g/m2静脉滴注。所有病例均于第2、23天给予顺铂75mg/m2静脉滴注。化疗2个周期后评价各组疗效和不良反应。结果 D1、D2、D3组之间,G1、G2、G3组之间的疗效和不良反应均无统计学差异。D1组与G1组、D2组与G2组之间的的疗效和不良反应亦无统计学差异;G3组有效率高于D3组(56.3%vs.33.3%)(P<0.05)。结论在20:00给药,吉西他滨的疗效优于多西他赛。Objective To compare the efficacy and adverse effects of docetaxel and gemcitabine given at different times of the day for treating advanced non-small cell lung cancer（NSCLC）.MethodsA total of 210 patients with pathologically diagnosed advanced NSCLC was equally divided into six groups of D1（intravenous infusion of docetaxel 40 mg/m2 at 8：00）,D2（docetaxel 40 mg/m2 at 14：00）,D3（docetaxel 40 mg/m2 at 20：00）,G1（intravenous infusion of gemcitabine 1 g/m2 at 8：00）,G2（gemcitabine 1 g/m2 at 14：00） and G3（gemcitabine 1 g/m2 at 20：00） on the 1st and 8th day.All patients were given additional intravenous infusion of cisplatin 75 mg/m2 on the 2nd and 23rd day.The efficacy and adverse effects were evaluated after two theraputic cycles.Results There was no statistical difference in efficacy and adverse effects among groups of D1,D2 and D3.So did among groups of G1,G2 and G3.There was no statistical difference in the efficacy and adverse effects between groups of D1 and G1 or groups of D2 and G2,while the effectiveness rate of group G3 was higher than that of group D3（56.3% vs.33.3%）（P0.05）.Conclusion The efficacy of gemcitabine is better than that of docetaxel when given at 20：00.

关 键 词：多西他赛 吉西他滨 时辰药效学 非小细胞肺癌 

分 类 号：R969[医药卫生—药理学]